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A B S T R A C T
Purpose
To compare overall survival (OS) for fulvestrant 500 mg versus anastrozole as first-line endocrine
therapy for advanced breast cancer.
Patients and Methods
The Fulvestrant First-Line Study Comparing Endocrine Treatments (FIRST) was a phase II,
randomized, open-label, multicenter trial. Postmenopausal women with estrogen receptor–
positive, locally advanced/metastatic breast cancer who had no previous therapy for advanced
disease received either fulvestrant 500 mg (days 0, 14, 28, and every 28 days thereafter) or
anastrozole 1 mg (daily). The primary end point (clinical benefit rate [72.5% and 67.0%]) and a
follow-up analysis (median time to progression [23.4 months and 13.1 months]) have been
reported previously for fulvestrant 500 mg and anastrozole, respectively. Subsequently, the
protocol was amended to assess OS by unadjusted log-rank test after approximately 65% of
patients had died. Treatment effect on OS across several subgroups was examined. Tolerability
was evaluated by adverse event monitoring.
Results
In total, 205 patients were randomly assigned (fulvestrant 500 mg, n  102; anastrozole, n  103).
At data cutoff, 61.8% (fulvestrant 500 mg, n  63) and 71.8% (anastrozole, n  74) had died. The
hazard ratio (95% CI) for OS with fulvestrant 500 mg versus anastrozole was 0.70 (0.50 to 0.98;
P  .04; median OS, 54.1 months v 48.4 months). Treatment effects seemed generally consistent
across the subgroups analyzed. No new safety issues were observed.
Conclusion
There are several limitations of this OS analysis, including that it was not planned in the original
protocol but instead was added after time-to-progression results were analyzed, and that not
all patients participated in additional OS follow-up. However, the present results suggest
fulvestrant 500 mg extends OS versus anastrozole. This finding now awaits prospective
confirmation in the larger phase III FALCON (Fulvestrant and Anastrozole Compared in
Hormonal Therapy Naïve Advanced Breast Cancer) trial (ClinicalTrials.gov identifier:
NCT01602380).
J Clin Oncol © 2015 by American Society of Clinical Oncology. Licensed under the Creative
Commons Attribution 3.0 License: http://creativecommons.org/licenses/by/3.0/
INTRODUCTION
Tamoxifen and third-generation aromatase inhibi-
tors (AIs), such as anastrozole, exemestane, and
letrozole are established first-line endocrine thera-
pies for the treatment of postmenopausal women
with estrogen receptor (ER) –positive, advanced
breast cancer.1-3 Given the high prevalence of resis-
tance to AI therapy, multiple treatment options with
distinct mechanisms of action are desirable.4
Fulvestrant, a 17-estradiol analog, is a selec-
tive ER antagonist that suppresses estrogen signaling
by binding to ER and inducing a conformational
change.5,6 Dimerization is subsequently blocked,
triggering accelerated degradation and downregula-
tion of the ER protein.5 Fulvestrant exhibits lack of
cross-reactivity with tamoxifen. Consequently, pa-
tients whose disease progresses on fulvestrant may
retain sensitivity to treatment with further endo-
crine therapies.7,8 The clinical efficacy of fulvestrant
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was initially demonstrated in two phase III trials that compared ful-
vestrant 250 mg per month with anastrozole 1 mg daily as a second-
line therapy for advanced breast cancer.9,10 A combined analysis of
these trials demonstrated that time to progression (TTP) with fulves-
trant 250 mg was noninferior to anastrozole.11
Fulvestrant 250 mg was not proven to be superior to tamoxifen in
a double-blind, randomized trial.12 This finding was unexpected given
the superiority of anastrozole over tamoxifen13 and the comparable
efficacy of anastrozole and fulvestrant 250 mg as second-line ther-
apy.11 Pharmacokinetic modeling, as well as observations made dur-
ing early clinical studies,11 suggested the efficacy of fulvestrant could
be improved with use of a higher dose, which led to the development
of a dosage regimen of fulvestrant 500 mg, including a loading dose
component to reduce the time to reach steady-state plasma levels.
Subsequently, the phase III Comparison of Faslodex in Recurrent
or Metastatic Breast Cancer (CONFIRM) trial found that fulves-
trant 500 mg was associated with improved progression-free sur-
vival (PFS) and overall survival (OS) compared with the 250-mg
dose in patients who experienced disease recurrence or progression
after previous endocrine therapy.14,15
The Fulvestrant First-Line Study Comparing Endocrine Treat-
ments (FIRST) was a phase II, randomized, open-label, multicenter
trial that also used the fulvestrant 500-mg dose regimen, comparing
efficacy and safety with anastrozole in the first-line setting. The pri-
mary end point of clinical benefit rate was noninferior for fulvestrant
500 mg compared with anastrozole,16 with both treatments demon-
strating similar, well-tolerated safety profiles. A follow-up analysis,
performed because only 35.6% of patients experienced disease pro-
gression at the time of the primary analysis, reported a hazard ratio
(HR) of TTP for fulvestrant 500 mg versus anastrozole of 0.66 with a
95% CI of 0.47 to 0.92 (P  .01; median TTP, 23.4 months v
13.1 months). No additional safety issues were reported.17 Given the
improvement in TTP observed during fulvestrant 500 mg treatment
compared with anastrozole in this phase II trial, a subsequent protocol
amendment was made to address whether this apparent extension in
disease control would translate into an improvement in OS.
PATIENTS AND METHODS
Study Design and Participants
FIRST was a phase II, randomized, open-label, multicenter, parallel-
group trial comparing fulvestrant 500 mg with anastrozole 1 mg. Postmeno-
pausal women with ER-positive locally advanced or metastatic breast cancer
who had not received any previous systemic therapy for locally advanced or
metastatic disease were included. Patients were permitted to have received
previous endocrine therapy for early disease, providing this had been com-
pleted more than 12 months before random assignment. This trial was con-
ducted in accordance with the Declaration of Helsinki, was consistent with the
International Conference on Harmonisation–Good Clinical Practice guide-
lines, and is registered with Clinicaltrials.gov. All patients provided written,
informed consent. Full details of this trial have been reported previously.16,17
Random Assignment and Procedures
Eligible patients were randomly assigned sequentially 1:1 to either fulves-
trant 500 mg (administered intramuscularly on days 0, 14, 28, and every
28 days thereafter) or anastrozole 1 mg (administered orally once per day). The
data cutoff for the primary analysis was 6 months after the last patient was
randomly assigned. On disease progression or after data cutoff for the primary
analysis, all patients entered a follow-up phase after a protocol amendment for
an analysis of TTP. The TTP follow-up required a questionnaire to be com-
pleted for each patient 12 months after the patient entered the follow-up phase
and every 12 months thereafter for patients continuing to receive randomized
treatment. After the TTP analysis was performed, a further protocol amend-
ment was developed to enter patients into an optional follow-up phase to
establish OS. To ensure sufficient maturity, the OS analysis was planned for
when approximately 65% of patients had died. Patients who did not contrib-
ute additional data to the follow-up extension were right-censored at the last
known date they were alive, and their data until this point were included in the
analysis. Sites were invited to request written consent from patients for the
collection of additional data. Patients were contacted every 3 months until the
first of the following events: death, patient withdrawal, data cutoff was reached,
or the patient was lost to follow-up. Patients with a last known survival status of
alive were contacted within 2 weeks of data cutoff to ensure they were still alive.
Outcomes
The primary study end point was clinical benefit rate; secondary end
points included objective response rate, TTP, duration of clinical benefit, and
duration of response. These primary and secondary end points have been
reported previously.16,17
The follow-up analysis assessed OS, defined as the time from being
randomly assigned to death from any cause. A log-rank test (unadjusted model
with treatment factor only) was performed for the primary analysis of OS. HRs
with 95% CIs were used to compare fulvestrant 500 mg with anastrozole; no
adjustments were made for multiplicity. A statistical significance level of .05
was used to indicate a difference in OS between the treatment groups. For
patients for whom follow-up responses could not be obtained, data were
censored at the date the patient was last known to be alive.
Exploratory subgroup analyses were conducted using the log-rank test to
compare OS for the following prespecified patient subgroups: less than
65 years of age versus 65 years of age or greater; not positive for both ER and
progesterone receptor versus positive for both ER and progesterone receptor;
no visceral involvement versus visceral involvement; no previous chemother-
apy versus previous adjuvant chemotherapy; no measurable disease versus
measurable disease; and no previous endocrine therapy versus previous endo-
crine therapy.
Two sensitivity analyses were performed to examine any potential
impact of nonparticipation on OS results: a Kaplan-Meier OS analysis was
performed in which the censoring indicator was reversed; and baseline
covariates were assessed for patients censored greater than 3 months before
data cutoff and for those censored 3 months or less before data cutoff,
which corresponds to patients who did not participate in the OS follow-up
and to those who did, respectively.
Tolerability was assessed by serious adverse event (SAE) monitoring. All
SAEs were coded in compliance with the Medical Dictionary for Regulatory
Activities and recorded in an internal AstraZeneca database for evaluation.
SAEs were monitored for up to 8 weeks after the last dose of fulvestrant 500 mg
or for 30 days after the last dose of anastrozole.
RESULTS
In total, 205 patients were randomly assigned to receive fulvestrant
500 mg (n  102) or anastrozole 1 mg (n  103) at 62 centers in nine
countries (Brazil, Bulgaria, the Czech Republic, France, Italy, Poland,
Spain, the United Kingdom, and the United States).
Baseline characteristics and patient demographics were similar
between the treatment groups as reported previously.16 The propor-
tion of patients who had not received previous endocrine treatment
for early disease was similar for the fulvestrant 500 mg and anastrozole
treatment groups (71.6% and 77.7% of patients at baseline, respec-
tively). Of those that did, almost all had received tamoxifen exclu-
sively. Of the 205 randomly assigned patients, 35 (16 in the fulvestrant
500 mg group and 19 in the anastrozole group) did not participate in
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the OS follow-up phase and were censored at the date they were last
known to be alive; for these patients, data until this time are
included in the OS analysis, and thus all patients contributed data
to the analysis. The majority of the nonparticipating patients (n 
20) did not contribute additional data because they attended cen-
ters that declined to contribute to the OS follow-up phase. An
additional 15 individual patients from nine participating centers
did not consent to follow-up. No patients participating in the OS
phase were lost to follow-up, and the survival status at data cutoff
was known for all patients consenting to the OS follow-up.
Efficacy
At the time of the follow-up analysis for OS, 63 of 102 patients in
the fulvestrant 500 mg group (61.8%) and 74 of 103 patients in the
anastrozole group (71.8%) were known to have died (Fig 1). The
primary analysis of OS was improved in the fulvestrant 500 mg group
compared with anastrozole 1 mg; the HR was 0.70 (95% CI, 0.50 to
0.98; log-rank test P  .04; median OS, 54.1 months v 48.4 months;
Fig 2). The HR for fulvestrant 500 mg versus anastrozole was found to
be generally consistent across all subgroup analyses (Fig 3). At 3 years,
64% (fulvestrant 500 mg) and 58% (anastrozole) of patients were
event free; at 5 years, the equivalent values were 47% and 38%.
Sensitivity Analyses
There were no important differences between the treatment
groups in time to censoring (data not shown). Furthermore, when key
baseline covariates for patients censored within the last 3 months
before data cutoff and for those censored more than 3 months before
data cutoff were summarized, there were no important differences
between treatment groups, indicating that the results were not caused
by differences between patients who did and did not consent to OS
follow-up (Table 1).
Safety
The occurrence of SAEs during the main study period and the
follow-up period combined is detailed in Table 2. The majority of
SAEs were considered by the investigator to be unrelated to the treat-
ment. Two SAEs considered to be treatment related were documented
(one case of hypertension and one case of pulmonary embolism, both
in the fulvestrant 500 mg treatment group).
DISCUSSION
This study reports improved OS with fulvestrant 500 mg treatment
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Fig 1. Study overview. (*) These patients
were right censored at the time of their last
known date alive, and data until this point
were used in the overall survival (OS) analysis.
Median overall survival:
  Fulvestrant 500 mg: 54.1 months
  Anastrozole 1 mg: 48.4 months
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Fig 2. Kaplan-Meier plot of overall survival.
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advanced breast cancer, with an approximately 30% reduction in
mortality risk. The previously reported improvements in TTP have
translated into an improvement in OS of approximately 6 months
with fulvestrant 500 mg (54.1 months) compared with anastrozole
(48.4 months). This OS advantage is consistent with the OS benefit for
fulvestrant 500 mg versus 250 mg in the second-line setting in the
CONFIRM trial.15 The effect of fulvestrant 500 mg on OS was gener-
ally consistent across all prespecified subgroups (Fig 3). Furthermore,
no new safety or tolerability issues were reported from the OS
follow-up phase of this study, consistent with previously reported
safety data.16,17
The improved OS with fulvestrant 500 mg (54.1 months) relative
to anastrozole (48.4 months) was observed although the median OS
for the anastrozole group in this study was higher than has previously
been reported. For example, OS of 39.2 months was reported for
anastrozole as first-line endocrine therapy for advanced breast cancer
Favors fulvestrant 500 mg Favors anastrozole
2.001.000.25 0.50
elozortsanA tnartsevluF 
oitar drazaH  gm 1 gm 005 
)IC %59( IC %59 dna oitar drazaH )n( stneve )n( stneve 
 
)89.0 ot 05.0( 07.0 )301( 47 )201( 36 stneitap llA
 
Age, years
)42.1 ot 44.0( 37.0 )04( 92 )54( 92 56 <  
  ≥ )60.1 ot 44.0( 86.0 )36( 54 )75( 43 56 
 
Both ER+ and PgR+
)23.1 ot 33.0( 66.0 )52( 81 )42( 41 oN  
)60.1 ot 94.0( 27.0 )87( 65 )87( 94 seY  
 
Visceral involvement
)81.1 ot 04.0( 86.0 )54( 62 )45( 92 oN  
)43.1 ot 65.0( 68.0 )85( 84 )84( 43 seY  
 
Prior chemotherapy
)49.0 ot 34.0( 36.0 )87( 75 )37( 34 oN  
)87.1 ot 84.0( 39.0 )52( 71 )92( 02 seY  
 
Measurable disease
CN         CN )01( 7 )31( 11 oN  
)69.0 ot 64.0( 76.0 )39( 76 )98( 25 seY  
 
Prior endocrine therapy
)39.0 ot 24.0( 36.0 )08( 95 )37( 44 oN  
)99.1 ot 15.0( 10.1 )32( 51 )92( 91 seY  
Fig 3. Overall survival subgroup analy-
sis. ER, estrogen receptor positive;
NC, not calculable; PgR, progesterone
receptor positive.
Table 1. Baseline Covariates and Subgroups by Patients Censored  3 Months and  3 Months Before DCO
Subgroup
No. of Patients (%)
Censored  3 Months Before DCO Censored  3 Months Before DCO
Fulvestrant 500 mg (n  16) Anastrozole 1 mg (n  19) Fulvestrant 500 mg (n  23) Anastrozole 1 mg (n  10)
Age, years
 65 5 (31.3) 7 (36.8) 11 (47.8) 4 (40.0)
 65 11 (68.8) 12 (63.2) 12 (52.2) 6 (60.0)
Receptor status at diagnosis
Not both ER and PgR 6 (37.5) 5 (26.3) 4 (17.4) 2 (20.0)
Both ER and PgR 10 (62.5) 14 (73.7) 19 (82.6) 8 (80.0)
Visceral involvement
No 9 (56.3) 11 (57.9) 16 (69.6) 8 (80.0)
Yes 7 (43.8) 8 (42.1) 7 (30.4) 2 (20.0)
Previous chemotherapy
No 11 (68.8) 13 (68.4) 19 (82.6) 8 (80.0)
Yes 5 (31.3) 6 (31.6) 4 (17.4) 2 (20.0)
Measurable disease at diagnosis
No 1 (6.3) 3 (15.8) 1 (4.3) 0
Yes 15 (93.8) 16 (84.2) 22 (95.7) 10 (100.0)
Previous endocrine therapy
No 11 (68.8) 13 (68.4) 18 (78.3) 8 (80.0)
Yes 5 (31.3) 6 (31.6) 5 (21.7) 2 (20.0)
Abbreviations: DCO, data cutoff; ER, estrogen receptor–positive; PgR, progesterone receptor–positive.
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in a combined analysis of two phase III studies,18 and OS of 41.3
months was reported for the anastrozole monotherapy arm of a phase
III combination study.19 In addition, corresponding median OS val-
ues of 34.0 months (letrozole)20 and 37.2 months (exemestane)21 have
been reported for other AIs. It is therefore unlikely that the present
analysis overestimates the margin of improvement with fulvestrant
500 mg over anastrozole, which might have been possible had the
control arm underperformed.
The role of fulvestrant 500 mg as first-line therapy will be further
defined by the ongoing phase III, double-blind FALCON (Fulvestrant
and Anastrozole Compared in Hormonal Therapy Naïve Advanced
Breast Cancer) trial (ClinicalTrials.gov identifier: NCT01602380). The
FALCONtrialwillassess theefficacyof fulvestrant500mgversusanastro-
zoleinwomenwithlocallyadvancedormetastaticbreastcancerwithstrict
definitions of endocrine therapy–naïve disease, including restrictions on
exposure to hormone replacement therapy.
Endocrine therapy–naïve advanced breast cancer is relatively un-
common in countries with advanced health care, but represents a
numerically substantial patient population, given the high disease
prevalence. Furthermore, in unscreened populations and in develop-
ing countries, metastatic disease at presentation is a significant prob-
lem. Recent clinical trials reporting on first-line endocrine therapy in
patients with ER-positive breast cancer have contained a substantial
proportion, and often a majority, of endocrine therapy–naïve
patients.19,22-24 In FIRST, previous endocrine therapy had been re-
ceived by 29 (28.4%) of the patients treated with fulvestrant 500 mg
and 23 (22.3%) of the anastrozole-treated patients. Of these 52 pa-
tients, only 3 had received AI previously (2 in the anastrozole group and
1 in the fulvestrant 500 mg group); the remainder had received adjuvant
tamoxifen. Therefore, AI resistance resulting from previous AI exposure
cannot account for the observed OS difference. Indeed, hypothetically,
previous exposure to tamoxifen may bias against fulvestrant as both
agents are in the same therapeutic class. Upon disease progression, pa-
tients were treated according to the standard of care, and therefore, there
could potentially be imbalances between the two treatment groups that
could have affected the OS analysis. However, response to subsequent
therapies (systemic chemotherapy or endocrine therapy) has previously
been shown to be similar between the treatment groups, demonstrating
that patients with disease progression on fulvestrant retain sensitivity to
subsequent treatments.17 Differential second-line response, therefore, is
also an unlikely explanation for the observed OS effect.
There are significant limitations to this report. The sample size was
relatively small, and the OS analysis was not specified in the original
protocol but was added as a hypothesis in a protocol amendment after
TTP results were known. Furthermore, 35 patients did not contribute
additional data to the OS follow-up; the decision not to participate in the
extendedfollow-upforOSwasmadesolelyby thepatientorparticipating
center and was known at the start of the OS follow-up and before the data
were collected and analyzed. Data from these patients until the time of
censoringwereincludedintheOSanalysis,andsimilarcensoringpatterns
were seen in the two treatment groups. The sensitivity analyses support
the main findings, that is, the differences in OS between treatment arms
were unrelated to differences in censoring patterns. All-cause mortality
wasusedtodetermineOSinthisanalysisbecauseit isregardedasthemost
unbiased and objective end point used in oncology.25 This point is partic-
ularly relevant to an open-label study like FIRST. A final limitation was
that the number of patients within subgroups was relatively small. There-
fore, care should be taken when interpreting results.
Recent results from several trials with the cyclin-dependent ki-
nase 4/6 (CDK4/6) inhibitor palbociclib are also pertinent to the
discussion. PALOMA-1 (Palbociclib Ongoing Trials in the Manage-
ment of Breast Cancer), a phase II trial of letrozole plus palbociclib
versus letrozole alone, provided provisional US Food and Drug Ad-
ministration approval for palbociclib in the first-line setting on the
basis of PFS.23 No positive OS data have been reported to date; the
results of a phase III trial of this comparison are pending (PALOMA-2,
NCT01740427). Data from the phase III PALOMA-3 trial, comparing
fulvestrant 500 mg plus palbociclib versus fulvestrant 500 mg alone in
the second-line or subsequent setting in postmenopausal women (or
pre- or perimenopausal women receiving goserelin), reported a
marked PFS advantage for the combination, but OS data were also
pending at the time of publication.26 The median PFS for fulvestrant
500 mg alone was shorter in PALOMA-3 than in previous studies,
indicative of the younger, higher-risk, and more heavily pretreated
population recruited into the PALOMA-3 trial.
The treatment algorithm for ER-positive advanced breast cancer,
therefore, is in a state of flux. Currently, it is rational to consider
fulvestrant 500 mg as a first-line treatment option given the potential
for survival benefits, particularly in settings where palbociclib is not
available or palbociclib cost or adverse effects are a significant concern,
and especially if these results are confirmed in FALCON. These data
also suggest that a first-line study of fulvestrant 500 mg with a CDK4/6
inhibitor versus fulvestrant 500 mg alone is a logical proposition that
could lead to further prolonged TTP. Recent preclinical data on the
efficacy of an ER degrading agent with a CDK4/6 inhibitor in ESR1-
mutant breast cancer provides further rationale for this population,
because improvements in TTP or OS could be caused by suppression
of ESR1-mutant AI-resistant clones.27
In conclusion, we report that fulvestrant 500 mg may be associ-
ated with improved OS versus anastrozole in the first-line setting for
ER-positive advanced breast cancer. To our knowledge, this repre-
sents the first time an endocrine monotherapy has demonstrated
Table 2. Incidence of SAEs and Deaths
SAE







Any SAE 24 (23.8) 22 (21.4)
Any SAE related to death 3 (3.0) 5 (4.9)
Any SAE with outcome other than death 21 (20.8) 18 (17.5)
Any causally related SAE 2 (2.0) 0
Most commonly reported ( two patients)
SAEs
Atrial fibrillation 1 (1.0) 1 (1.0)
Cardiac failure 2 (2.0) 0
Death 0 2 (1.9)
Decreased appetite 2 (2.0) 0
Dehydration 2 (2.0) 0
Dyspnea 2 (2.0) 0
Femur fracture 1 (1.0) 2 (1.9)
Neuralgia 1 (1.0) 1 (1.0)
Transient ischemic attack 0 2 (1.9)
Abbreviation: SAE, serious adverse event.
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improved efficacy compared with a third-generation AI. The phase III
FALCON trial may provide confirmation for these OS results; until
then, the findings reported here should be regarded as preliminary,
but clinically relevant.
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GLOSSARY TERMS
Anastrozole: a third-generation nonsteroidal aromatase in-
hibitor that prevents the conversion of androgen to estrogen in
the peripheral tissues in postmenopausal women. Because
hormone-dependent breast cancer progresses with estrogen,
anastrozole has been used in the treatment of breast cancer in
postmenopausal women. See aromatase inhibitors.
Aromatase inhibitors: inhibitors used in treating breast cancer
in postmenopausal women. Aromatase inhibitors inhibit the conversion
of androgens to estrogens by the enzyme aromatase, thus depriving the
tumor of estrogenic signals. Because of decreased production of estro-
gen, estrogen receptors, which are important in the progression of breast
cancer, cannot be activated.
Estrogen receptor (ER): ligand-activated nuclear proteins, be-
longing to the class of nuclear receptors, present in many breast cancer
cells that are important in the progression of hormone-dependent can-
cers. After binding, the receptor-ligand complex activates gene tran-
scription. There are two types of estrogen receptors (ER and ER).
ER is one of the most important proteins controlling breast cancer
function. ER is present in much lower levels in breast cancer, and its
function is uncertain. Estrogen receptor status guides therapeutic deci-
sions in breast cancer.
Overall survival: the duration between random assignment and
death.
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